Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
SkyePharma
SkyePharma
Activities:
Manufacturing
Drug Delivery
Pharmaceutical
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Drug Delivery
SkyePharma signs exclusive licensing agreement to access Lucideon’s abuse deterrent drug delivery technology
First product to be developed for the growing $11bn US opioid market
Manufacturing
Skyepharma installs MG2 Planeta
To address its needs for the production of pilot and clinical batches of inhalation products and third party projects
Research & Development
David Lescuyer joins SkyePharma as Executive Vice President, Oral Business
He will be responsible for Skyepharma’s Oral Business including, after 30 June, the manufacturing operations in Saint-Quentin Fallavier, France
Finance
Vectura and Skyepharma agree to merge
Respiratory drug delivery specialists will become an industry-leading airways-related speciality business
Research & Development
Skyepharma acquires novel inhaled therapy platform
New product opportunity to be developed as an anti-inflammatory treatment for COPD
Drug Delivery
Flutiform sales drive growth at SkyePharma
Plans to raise £112m in capital to pay off bond debt and strengthen product pipeline
Drug Delivery
SkyePharma reports strong revenue growth
Underpinned by sales of Flutiform and use of proprietary dry powder formulation technology in GSK product
Subscribe now